HOUSTON--(BUSINESS WIRE)--Vyripharm Biopharmaceuticals, a subsidiary of Vyripharm Enterprises, LLC, a privately held company located in the Texas Medical Center in Houston, Texas, announced today that it has signed off on a Master Drug Program Agreement with Regis Technologies, Inc. Regis is a privately held contract development manufacturing organization (CDMO) in Morton Grove, Illinois. The agreement allows Vyripharm to further develop its antiviral diagnostic agents to first-in-humans studies of viral infections such as SARS, MERS and COVID-19.
With the ongoing COVID-19 pandemic, the pharmaceutical and medical industry is working around the clock to develop treatments, vaccines and accurate in-vitro testing applications of the viral infection. While two therapeutic agents, remdesivir and plaquenil, biologically have demonstrated mild disease control in very severe symptomatic patients; there still remains a need for developing treatment for the larger patient population as well as a vaccine to ultimately control widespread transmission. Furthermore, an overlooked need is the ability to accurately diagnose and evaluate the severity of the disease. Like many diseases, there appears to be varying COVID-19 patient profiles, where predictability of symptomatic response or clinical indications based on profiles have yet to be determined. Vyripharm seeks to apply its platform technology to address an in-vivo human diagnostic antiviral imaging agents for the evaluation and treatment outcomes.
Thus, the emergence of the COVID-19 pandemic has created the critical need for new strategies for diagnosis, evaluation, treatment and treatment outcomes; Vyripharm has redirected efforts with its platform technology towards diagnostic intervention of viral infections. Vyripharm’s drug platform technology includes an anti-viral (VYR-2020) and a CB1 antagonist (VYR-206) that integrates nuclear medicine imaging and diagnostic applications. Vyripharm’s technology has the potential to provide early onset diagnosis; infection monitoring; severity evaluation and ultimately treatment outcomes of COVID-19.
Vyripharm recognizing the need for expediting our efforts and having a Master Drug Program Agreement with Regis Technologies, Inc., a leading company in developing drug candidates to market made just good sense to do so at this present time in reference to the pandemic. Regis has agreed to scale up our drug candidates, VYR-2020 and VYR-206, for process research, preclinical (animal studies) and clinical (first-in-humans). More importantly, Regis is a company that has worked with pharmaceutical and biotechnology companies for over 60 years to develop active pharmaceutical ingredients (APIs) and high value intermediates under GMP manufacture. Again, with a Drug Manufacture Agreement in place with Regis, Vyripharm feels confident that we will advance our efforts in a timely and cost-effective manner.
About Vyripharm Biopharmaceuticals
Vyripharm is a biopharmaceutical firm focused in neurological disorders and cancer. Our mission is the integration of Traditional medicine with Alternative medicine. The company has patents in sectors such as Regulatory Testing, Pharmaceutical and Diagnostic Drugs, Bioinformatics, Medical Informatics, Monitoring Technology, and Drug Delivery Systems. The company holds exclusive licenses, issued patents, patents pending and trademarks. For more information visit www.vyripharmbio.com
About Regis Technology:
Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help expedite their drug candidates to market. Regis has the necessary technical and operational capabilities to fully support its clients' preclinical and clinical API needs. We offer a full range of services to support the development of our clients' lead molecules through commercialization, including process research and development, analytical and stability services, CGMP API manufacturing. Regis is privately owned and operated and has been in business in the Chicago area since 1956.